At the University of Nebraska Medical Center, HIV care providers scrambled to set up new systems in hopes of maintaining retention in care and viral suppression among as many patients as possible.
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
For some clients, escalation is how they communicate that they feel unsafe or feel that their needs are not being taken seriously.
Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
Re-entry planning can help prevent opioid overdose and enable people living with HIV to connect with and stay in care.
A systematic review of research between 2000 and 2016 found no studies of interventions specifically designed to support medication adherence among HIV-positive black women.
Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.
Having Fallen Out of Care, Most Gay and Bisexual Men With Detectable HIV Viral Loads Were Successfully Reconnected, Study Finds
The study enrolled more than a thousand people in four U.S. cities: Atlanta, Baltimore, Birmingham, and Boston.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
There are a number of measures determine adherence to PrEP, each with benefits and drawbacks. Currently, no one guideline or definitive standard is being used.